echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > "Iprazole sodium for injection" of Lizhu pharmaceutical is about to go on the market, and analysts expect it to be 1 billion + "heavyweight"

    "Iprazole sodium for injection" of Lizhu pharmaceutical is about to go on the market, and analysts expect it to be 1 billion + "heavyweight"

    • Last Update: 2018-01-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: medicine magic cube January 2, 2018, Lizhu pharmaceutical announced that the approval status of the registration application for production of iprazole sodium for injection was changed to "approved - to be prepared" Eprazole is a new generation PPI inhibitor (benzimidazole proton pump inhibitor), which is the only innovative drug in the field of digestion in China Its enteric coated tablets were approved by CFDA on December 11, 2007, and were used for the treatment of duodenal ulcer The sales volume in 2016 was 285 million yuan The sales volume of liprazole enteric coated tablets of Lizhu pharmaceutical was omeprazole, lansoprazole and pantoprazole in 1988, 1995 and 1994 respectively, which were the first batch of PPI inhibitors In 2015, the sales volume of sample hospitals reached 1 billion yuan, 1.35 billion yuan and 1.23 billion yuan respectively Southwest Securities pointed out that considering that the same kinds of lansoprazole, pantoprazole, omeprazole and esomeprazole are all above 1 billion level, the eprazole sodium for injection is also expected to become 1-2 billion level heavyweight Huatai Securities pharmaceutical team pointed out that eprazole is the second generation of me better PPI with outstanding characteristics At present, there are six major players in the PPI market (the total scale is about 25 billion yuan), among which eprazole is the latest on the market, with outstanding clinical efficiency (no acid breakthrough at night, no CYP2C19 enzyme metabolism is required), and the analyst conservatively looks at the market scale of 2 billion yuan (oral: 500 million, injection: 1.5 billion) The listing application of iprazole sodium for injection was accepted by CDE on June 29, 2016, and entered the priority review list on October 28, 2016 Lizhu pharmaceutical has invested more than 100 million yuan in the R & D of this product.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.